^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | vadastuximab talirine (SGN-CD33A) (DNA replication inhibitor, CD33-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic Effect of SGN-CD33A and FLT3 Inhibitors in FLT3/ITD Acute Myeloid Leukemia
Published date:
11/01/2018
Excerpt:
Moreover, in most of the experiments in FLT3/ITD-positive cell lines the dose combination producing the highest synergistic effect was within one log of the IC50 for both SGN-CD33A and the FLT3i
Secondary therapy:
FLT3 inhibitor
DOI:
10.1182/blood-2018-99-116466
